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drain plus drain-clamping to reduce blood loss in
cementless total knee arthroplasty
Hirotaka Mutsuzaki1* and Kotaro Ikeda2Abstract
Background: Patients undergoing cementless total knee arthroplasty (TKA) sometimes suffer large blood loss. In a
retrospective study, we explored whether postoperative intra-articular retrograde injection of tranexamic acid (TA)
and leaving a drain clamp in place for 1 h reduced blood loss.
Patients and methods: Patients (n= 140) treated with unilateral primary cementless TKA (posterior cruciate
ligament retained) were divided into two groups: those who had an intra-articular injection of TA (1000 mg) and
drain clamping for 1 h postoperatively (study group, n= 70) and those who were not given TA and did not
undergo clamping of their drains (control group, n= 70). Postoperative total blood loss, volume of drainage,
hemoglobin level, transfusion amounts and rates, D-dimer level at postoperative day (POD) 7, and complications
were recorded.
Results: Total blood loss, total drainage, mean transfusion volume, and transfusion rates were lower in the study
group than in controls (P< 0.001). Hemoglobin levels on PODs 1 and 14 were similar in the groups, but on POD 7
the hemoglobin level was higher in the study group than in controls (P< 0.001). D-dimer level on POD 7 was lower
in the study group than in controls (P< 0.05). There were no complications in either group.
Conclusions: Immediately postoperative intra-articular retrograde injection of TA and 1 h of drain-clamping
effectively reduced blood loss and blood transfusion after cementless TKA. We believe that this method is simple,
easy, and suitable for these patients.
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Blood loss is unavoidable after total knee arthroplasty
(TKA) [1-3]. Controlling perioperative blood loss is es-
pecially a major concern with cementless TKA [4-7].
Two recent meta-analyses were performed to evaluate
the use of intravenous tranexamic acid (TA) to reduce
blood loss and the need for transfusion after total hip
arthroplasty and TKA [8,9]. Based on the results of clin-
ical trials considered suitable for evaluation, it was con-
cluded that TA appears to be a cost-effective, safe
method to reduce blood loss, and thus the need for* Correspondence: mutsuzaki@ipu.ac.jp
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distribution, and reproduction in any mediumallogenic blood transfusion, without increasing thrombo-
embolic complications.
Tranexamic acid inhibits tissue fibrinolysis for up to
17 h and consequently stabilizes the possibility of clots
entering the extravascular space and accumulating in tis-
sues [10]. It is generally accepted, however, that only a
small percentage of intravenously injected TA reaches
the target location. Thus, a more efficient method
(i.e., intra-articular injection) to deliver TA is desirable
[11,12]. Another method used to reduce blood loss is
drain-clamping [13-18].
One strategy for reducing blood loss after cementless
TKA includes drain-clamping combined with intra-
articular administration of TA plus carbazochrome so-
dium sulfonate and fibrin glue [19]. We modified that
method to make it simpler, easy to use, suitable for theseCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tered TA intra-articularly after cementless TKA, inject-
ing it retrogradely through the drain at the end of the
operation and then clamped the drain for 1 h.
The effect of this treatment on reducing postoperative
bleeding after cementless TKA has not been reported.
Our hypothesis was that intra-articular administration of
TA via the drain and then clamping the drain for an
hour would reduce postoperative bleeding after cement-
less TKA.
Patients and methods
This study, conducted from June 2007 through March
2012, was nonrandomized and retrospective. It included
140 knees undergoing unilateral primary cementless
TKA (retaining the posterior cruciate ligament). The
ethics committee of Ichihara Hospital reviewed and
approved the study (the reference number for the ethics
approval: 1202, and the trial registration number: 1202).
Informed consent was obtained from each patient. Ex-
clusion criteria were known allergy to TA, cemented
TKA, bilateral TKAs, and posterior stabilized TKA.
After these exclusions, 140 patients remained. They were
divided into two groups. The study group underwent
retrograde intra-articular injection of TA via the drain at
the end of the operation followed by clamping the drain
for 1 h (n = 70) (from January 2010 through March
2012). The control group did not undergo this treatment
(n = 70) (from June 2007 through October 2009). The
preoperative characteristics, including age, sex, any knee
disease, height, weight, preoperative femorotibial angle,
range of motion of the knee, and hemoglobin levels 1
day before surgery were comparable in the two groups
(Table 1). The backgrounds of the patients in the groups
were not significantly different. All surgery was per-
formed or supervised by a single surgeon (K.I.).
All patients were given general anesthesia. The patella
was not replaced, the posterior curuciate ligament was
retained, and all components were fixed without cement
in all 140 patients. Surgery was performed underTable 1 Patient profiles
Study group (n=70)
Age (year) 72.0 ± 7.3
Sex (male/female) 16/54
Disease (OA/RA) 68/2
Height (cm) 150.7 ± 8.0
Body weight (kg) 62.3 ± 11.0
Preoperative FTA (°) 184.8 ± 6.5
Preoperative ROM (°) 108.2 ± 25.4
Preoperative Hb (g/dl) 12.6 ± 1.4
OA osteoarthritis, RA rheumatoid arthritis, FTA femorotibial angle, ROM range of mo
Results are the mean ± SD.tourniquet control. After a midline skin incision was
made, a medial parapatellar approach was used. An
intramedullary alignment rod was used for femoral cut-
ting and an extramedullary guide system for tibial cut-
ting. The femoral canal for intramedullary guidance was
routinely plugged with bone. We did not use red cell sal-
vaging device.
The implants used in all patients were the Scorpio
NRG CR HA (Stryker Howmedica Osteonics, Allendale,
NJ, USA) or the NexGen CR (Zimmer, Warsaw, IN,
USA). With the NexGen CR type, the femoral compo-
nent was HA-TCP CR Femoral or CR-flex Porus Fem-
oral. The tibial component was NexGen CR HA-TCP
Tibia Peg, NexGen CR HA-TCP Stem Tibia, or NexGen
Trabecular Metal Monoblock Tibia. Scorpio NRG CR
HA was used in 19 knees in the study group and 37
knees in the control group. NexGen CR type was used
in 51 knees in the study group and 33 knees in the con-
trol group. NexGen CR HA-TCP Tibia Peg was used in
3 knees in the study group and 15 knees in the control
group. NexGen CR HA-TCP Stem Tibia was used in 13
knees in the study group and 18 knees in the control
group. NexGen Trabecular Metal Monoblock Tibia was
used in 35 knees in the study group and 0 knees in the
control group. HA-TCP CR Femoral was used in 21
knees in the study group and 33 knees in the control
group. CR-flex Porus Femoral was used in 30 knees in
the study group and 0 knees in the control group. The
implant types used were not significantly different in the
two groups using the Mann–Whitney U-test (P = 0.591).
Because of the reduced blood loss, the tourniquet was
not released until skin closure and application of a com-
pressive dressing [20]. Intraoperative blood loss was neg-
ligible in all patients because the tourniquet was not
deflated until wound closure. We used an intra-articular
drain connected to a vacuum bag (J-VAC suction reser-
voir 450 ml; Johnson & Johnson K.K., Tokyo, Japan). In
the study group, intra-articular administration of TA was
injected via the drain retrogradely before releasing of the
tourniquet, and the drain was then clamped for 1 h. WeControl group (n=70) P value
74.1 ± 7.1 NS
17/53 NS
69/1 NS
150.9 ± 7.8 NS
63.1 ± 9.5 NS
184.7 ± 8.0 NS
114.3 ± 18.2 NS
12.7 ± 1.4 NS
tion, Hb hemoglobin.
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clamping was effective [17]. Also, 1 h of clamping is sim-
ple and understandable for clinicians.
The amount of TA to be injected was chosen to be 1
ampoule (10% Transamin, 10 ml, 1000 mg; Daiichi-
Sankyo, Tokyo, Japan). This dose was found acceptable
in previous studies [4-8]. Also, a single ampoule is a sim-
ple quantity and understandable for clinicians. In both
groups in our study, the drains were removed 48 h after
the operation.
Following surgery, all patients underwent intravenous
prophylactic antibiotic therapy consisting of 1 g cefazolin
every 12 h for 3 days. Standard thromboprophylaxis was
also prescribed for all patients after surgery. It was admi-
nistered subcutaneously and included 1.5–2.5 mg fonda-
parinux sodium (ArixtraW Injection; Glaxo-Smith-Kline,
Brentford, Middlesex, UK) starting 24 h after surgery
and continuing every 24 h for 10 days. A foot pump
(Novamedix A-V Impulse System; Kobayashi Medical,
Osaka, Japan) and antiembolic stockings (AnsilkW;
ALCARE, Tokyo, Japan) were used for thromboembolic
prophylaxis [21,22].
Sutures were removed from all patients 2 weeks after
surgery. As part of the postoperative care for both
groups, continuous passive movement was started on
postoperative day (POD) 3, and standing and full
weight-bearing walking were allowed 1 week after the
operation.
If possible, autologous blood was collected on pre-
operative day 4 or earlier. Indications for preoperative
autologous blood donations were based on the Standards
for Preoperative Autologous Blood Donations (2007)
developed by the Japanese Society of Autologous Blood
Transfusions. A blood hemoglobin level of ≥ 11.0 g/dl or
a hematocrit of ≥ 33% was required. No age limit was
established. Iron injection was administered at a dose of
80 mg at blood collection. When collection of ≥ 800 ml
of blood took ≥ 1 week, 24,000 units of recombinant
human erythropoietin (ESPOW, epoetinum alfa; Kyowa
Kirin, Tokyo, Japan) was administered subcutaneously.
On POD 1, all the autologous blood was transfused to
each patient.
We used the principle of transfusion based on the cri-
teria and guidelines for perioperative transfusion sug-
gested by the National Institutes of Health Consensus
Conference, which states that the decision to transfuse
blood depends on clinical assessment aided by labora-
tory data indicating that the patient has symptoms and
signs associated with acute anemia [23]. Therefore, our
indication for blood transfusion was set at a hemoglobin
concentration of 8.5 g/dl or a postoperative hemoglobin
level of 8.5–9.0 g/dl with clinical evidence of acute
anemia [24]. It may be adjusted according to the
patient’s cardiovascular status.Bleeding-related outcome measures included drained-
blood loss, total postoperative blood loss, need for auto-
genic or allogenic blood transfusions, and the transfu-
sion rate. Hemoglobin levels were measured on PODs 1,
7, and 14. A formula proposed by Nadler et al. [25] and
Sehat et al. [26] was used to calculate the total post-
operative blood loss. It was based on the maximum
postoperative decrease in hemoglobin level adjusted for
the weight and height of the patient. The loss of Hb was
then estimated according to the following formula:
Blood volume lð Þ ¼ height mð Þ3x 0:356
þ body weightðkgÞ x0:033
þ 0:183ðwomanÞ
¼ height mð Þ3x0:367
þ body weightðkgÞx0:032
þ 0:604ðmanÞHblossðgÞ
¼ Blood volumex10x ðHbi HbfinÞ
þHbtTotal blood lossðmlÞ
¼ Hbloss=Hbix100
where Hbloss (g) was the amount of Hb lost, Hbi (g/dl)
was the Hb concentration before surgery, Hbfin (g/dl)
was the Hb concentration on POD 7, and Hbt (g) was
the total amount of allogeneic and autologous Hb
transfused.
We recorded the operating time, and the D-dimer
level was assayed 7 days after the surgery. We also moni-
tored the wound condition (skin necrosis, hematoma, in-
fection) and the possibility of deep venous thrombosis
(DVT) and/or pulmonary embolism (PE) for 4 weeks
after the operation.
Statistical analyses
Student’s t-test was used to analyze parametric data, and
the Mann–Whitney U-test was used for nonparametric
data. P ≤ 0.05 was considered a significant difference.
Results
The results are summarized in Table 2. The total blood
loss was less in the study group than in the control group
(633.8 ± 317.2 vs. 1276.0 ± 327.1 ml, P < 0.001). The total
drainage during 0–48 h postoperatively was less in the
study group than in the control group (271.1 ± 201.8 vs.
506.4 ± 256.8 ml, P < 0.001). There was a greater reduc-
tion in both autogenic and allogeneic transfusion rates in
the study group than in the control group (10.0% vs.
65.7%, P < 0.001 and 10.0% vs. 31.4%, P < 0.001, respect-
ively). The mean amounts of transfusion per patient for
both autogenic and allogeneic transfusions were less in
the study group than in the control group (40.0 ± 120.9
vs. 264.1 ± 195.5 ml, P < 0.001 and 0.2 ± 0.7 vs. 1.1 ± 1.7
units, P < 0.001, respectively). The hemoglobin level on
POD 1 was similar in the two groups, but on POD 7 it
Table 2 Postoperative data for all patients
Parameter Study group (n=70) Control group (n=70) P value
Operative time (min) 68.8 ± 14.2 82.7 ± 16.8 < 0.001
Postoperative Hb (g/dl)
POD 1 11.3 ± 1.2 11.1 ± 1.3 NS
POD 7 10.7 ± 1.3 10.1 ± 1.1 < 0.001
POD 14 10.9 ± 1.1 10.7 ± 1.0 NS
Blood loss (ml)
Drained 271.1 ± 201.8 506.4 ± 256.8 < 0.001
Total 633.8 ± 317.2 1276.0 ± 327.1 < 0.001
Transfusions
Autologous (ml) 40.0 ± 120.9 264.1 ± 195.5 < 0.001
Allogeneic (units) 0.2 ± 0.7 1.1 ± 1.7 < 0.001
Transfusion rate (%)
Autologous 10.0 65.7 < 0.001
Allogeneic 10.0 31.4 < 0.001
D-dimer level 7days after surgery (μg/ml) 6.8 ± 2.4 7.7 ± 3.8 0.042
Results are the mean ± SD.
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(10.7 ± 1.3 g/dl vs. 10.1 ± 1.1 g/dl, P < 0.001).
The operating time was shorter in the study group than
in the control group (68.8 ± 14.2 vs. 82.7 ± 16.8 min, P <
0.001). There were no significant differences in the two
groups regarding the implant types. The D-dimer level,
measured on POD 7, was lower in the study group than in
the control group (6.8 ± 2.4 vs. 7.7 ± 3.8 μg/ml, P =
0.042). Finally, symptomatic deep vein thrombosis, pul-
monary embolism, and wound trouble including necrosis,
infection, and hematoma were not observed in either
group.
Discussion
The most important finding of the present study was
that intra-articular retrograde injection of TA via the
drain at the end of the operation and then clamping the
drain for 1 h effectively reduced postoperative blood loss
and thus the need for blood transfusion after cementless
TKA. This method is simple, easy to perform, suitable
for these patients, and understandable for clinicians. Al-
though, the total blood loss in the controls was greater
than that of previous studies [4,5], the use of fondapari-
nux sodium for thromboprophylaxis can be influenced.
The effect of TA and drain-clamping in patients under-
going cementless TKA was certainly clarified, similar to
previous studies [11-18].
The fibrinolytic system is activated transiently after
any surgery [27]. Tranexamic acid is a synthetic amino
acid that inhibits fibrinolysis by reversibly blockading
lysine-binding sites on plasminogen molecules, thereby
inhibiting its activation. This prevents plasmin frombinding with fibrinogen and fibrin structures after clot
formation [28]. Because of its antifibrinolytic effects, the
risk of increasing venous thromboembolism when using
TA is a cause for concern [29,30]. Tranexamic acid does
not influence fibrinolytic activity in vein walls, however
[30]. Therefore, neither our study nor previous studies
observed a greater incidence of venous thrombosis in
patients treated with TA [31-33]. Also, the D-dimer level
in the study group was lower than that in the control
group. The incidence of subcutaneous and intra-joint
hematomas was reduced in the study group compared
to the control group because of the small amount of
bleeding after TKA.
One of the main problems after TKA is the need for
blood transfusion. Although the incidence is low, serious
complications involving allogeneic blood transfusions
(e.g., viral infections, graft-versus-host disease) have been
reported [34]. Because the need for blood transfusion was
reduced using our method, transfusion-associated compli-
cations were reduced. Intra-articular TA application after
TKA has recently been introduced and has proved to re-
duce significantly postoperative blood loss and knee swel-
ling [11,12]. It can also reduce the dose of TA needed to
reduce postoperative blood loss [12]. Disadvantages of
intravenous TA are prolonged high systemic drug levels
from multiple injections or continuous infusion, leading
to drug-induced systemic thromboembolic events [8,9].
Further investigations using smaller amounts of TA than
were given in this study may be required.
In our study, the operating time was longer for the
control group than for the study group. This finding
may have been influenced by our use of different
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block Tibia implant had a trend to be used more often
in the study group than in the control group. The tibial
base plate of this device originally was fixed with a poly-
ethylene insert. Also, screws were not used for fixation
of the tibia to the tibial base plate. Other tibial base
plates have screws that fix the tibia and separate the
polyethylene insert. Increased time may be required for
operations in which screws are used for fixation of the
tibia to the base plate and for inserting polyethylene. Al-
though it is unclear whether there was greater blood loss
in the control group, a longer operating time does not
imply a greater chance of postoperative bleeding [35].
Further investigations using the same implant may be
required.
The study has limitations. First, it was retrospective.
Although there were no differences in patient character-
istics in the two groups, selection bias was not com-
pletely excluded. Second, more studies (randomized
controlled trials) are needed to determine dosage and
administration. Also, investigations using thrombo-
embolism screening tests such as ultrasonography may
be required.
Intra-articular injection of TA retrogradely via the
drain at the end of the operation and clamping the drain
for 1 h effectively reduced postoperative blood loss and
the need for blood transfusion after cementless TKA.
We believe that our modifications of this technique have
made it a simple, easy-to-use method that is suitable for
these patients and understandable for clinicians.
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